Veralipride (Agreal, Agradil) is a typical antipsychotic of the benzamide class. It is indicated for the treatment of vasomotor symptoms associated with menopause. It is a D2 receptor antagonist and it induces prolactin secretion without any estrogenic or progestagenic effects.[1] It was first authorised for use in 1979. Veralipride has never gained approval in the United States.

In September 2006, it was withdrawn from the Spanish market. As a result, the European Commission referred the matter to the European Medicines Agency (EMA). In July 2007, the EMA recommended the withdrawal of marketing authorisations for veralipride.[2]

See also

References

  1. ^ Carranza-Lira S (September 2010). "Actual status of veralipride use". Clinical Interventions in Aging. 5: 271–6. doi:10.2147/cia.s12640. PMC 2938034. PMID 20852674.
  2. ^ "Overall Summary of the Scientific Evaluation of Medicinal Products Containing Veralipride" (PDF). EMEA.